Norway-based Nordic Nanovector ASA (OSE: NANO) has named Dr Christine Wilkinson Blanc as its new Chief Medical Officer effective immediately, it was reported on Monday.
Dr Blanc has more than 25 years of experience in the pharmaceutical industry. She was the medical director of Phi-Medics for 10 years. She was also the medical director in Oncology for various companies including Ariad Pharma, Roche, GE Healthcare and Aventis.
Lars Nieba, Nano's interim chief executive officer, said, 'I am very pleased that Christine has joined Nordic Nanovector as CMO. Her vast experience in clinical development, particularly in oncology and haematology, will be invaluable as we focus our resources and energy on completing the PARADIGME study.'
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886